Munclinger M, Kautzner J, Serf B
II. interní katedra fakulty vseobecného lékarství Univerzity Karlovy, Praha.
Cas Lek Cesk. 1990 Apr 6;129(14):424-8.
Prostaglandin E1. (Prostavasin, Schwarz, FRG) was administered in a short-term infusion, 5-30 ng/kg/min., to five patients with precapillary pulmonary hypertension associated with lung disease. Significant pulmonary vasodilatation characterized by a drop of the median pressure in the pulmonary artery by 15% and of the pulmonary vascular resistance by 31% was achieved only in two patients. The authors observed a minimal incidence of side-effects; systemic hypotension observed in three patients was an undesirable manifestaútion. Prostaglandin E1 extends possibilities of a vasodilatating influence on precapillary pulmonary hypertension in lung disease. With regard to the different individual reactivity of patients it should be administered in this indication only under conditions of haemodynamic monitoring.
前列腺素E1（Prostavasin，施瓦茨公司，联邦德国）以5 - 30纳克/千克/分钟的速度进行短期输注，用于治疗5例与肺部疾病相关的毛细血管前性肺动脉高压患者。仅在2例患者中实现了显著的肺血管扩张，其特征为肺动脉平均压下降15%，肺血管阻力下降31%。作者观察到副作用发生率极低；3例患者出现的全身性低血压是不良表现。前列腺素E1扩展了对肺部疾病中毛细血管前性肺动脉高压进行血管扩张作用的可能性。鉴于患者个体反应不同，仅应在血流动力学监测条件下用于该适应症。
